CXCR4 antagonist (HSC mobiliser)
Plerixafor
Brand names: Mozobil
Adult dose
Dose: 240 micrograms/kg SC 6–11h before apheresis (after G-CSF priming); max 7 consecutive days
Route: SC
Frequency: once daily during mobilisation
Dose adjustments
Renal
Reduce dose if CrCl ≤50 mL/min
Clinical pearls
- Autologous stem-cell mobilisation in NHL/multiple myeloma after G-CSF
- Specialist haem
Contraindications
- Hypersensitivity
- Pregnancy/breastfeeding
Side effects
- Injection-site reactions
- GI upset
- Headache
- Splenomegaly/rupture (rare)
- Tumour mobilisation (theoretical risk in haematological malignancy)
Monitoring
- FBC
- CD34+ count
- Renal function
Reference: BNF; NICE TA483; SmPC; https://bnf.nice.org.uk/drugs/plerixafor/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO